Bubs shares soars over 43% following the US deal to send millions of baby formula tins

Bubs Australia (ASX: BUB) announced that the USA Food and Drug Administration (FDA) has exercised its discretion for Bubs to import six infant formula to import six infant formula products into the US with immediate effect.

At present, the Company is working with the U.S. Department of Health and Human Services to determine the best option for delivering products to the United States. The Company would provide at least 1.25 million tins in coming weeks and months, equivalent to minimum 27.5 million bottles across Bubs SupremeTM A2 Beta-Casein Protein, Bubs Organic® Grass Fed and Bubs® Easy-Digest Goat Milk Infant Formula products. 

At AEST 11:11 AM, BUB shares are trading at AU$0.695, up 43.298% from the previous close. 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Suite 1A, Level 2, 802-808 Pacific Highway, Gordon NSW 2072, Australia | 1800 005 780 | info@kapitales.com.au